Trial Profile
A randomized phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Fluorouracil; Gimeracil/oteracil/tegafur; Irinotecan; Levofolinic acid
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms TRUSTY
- Sponsors Taiho Pharmaceutical
- 09 Jan 2024 Results of exploratory biomarker analysis investigating the relationship between baseline plasma concentrations of angiogenesis-related factors and cell-free DNA (cfDNA), and the efficacy of FTD/TPI plus bevacizumab in patients with mCRC, published in the Targeted Oncology
- 04 Mar 2023 Results published in the British Journal of Cancer
- 22 Jan 2022 Results of post-hoc analysis assssing baseline tumor burden presented at the 2022 Gastrointestinal Cancers Symposium